Advancements in Prostate Cancer Using Multi-Omics
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 August 2026 | Viewed by 121
Special Issue Editors
Interests: prostate cancer; genomics
Interests: genomics; epigenomics; multi-omics; metastasis; treatment resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multi-omic technologies have greatly expanded our understanding of prostate cancer progression, heterogeneity, and treatment response. Integrated analyses incorporating genomic, epigenomic, transcriptomic, or proteomic information have made significant contributions to the field, spurring notable advancements. Novel insights into tumor microenvironment interactions, androgen receptor signaling, responses to novel treatment modalities, and immune modulation continue to emerge, especially when researchers utilize clinical specimens with these technologies. Advances in single-cell and spatial multi-omics are especially exciting, as they expand our ability to resolve cellular complexity in prostate cancer. This Special Issue aims to highlight novel discoveries in prostate cancer made using integrated analyses of omics technologies. The goal of this collection is to enhance our understanding of transforming these data into clinically relevant and translational information, and to shine a spotlight on such discoveries, representing significant contributions to this research field.
Dr. Megan Ludwig
Guest Editor
Dr. Justin H. Hwang
Co-Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- genomics
- transcriptomics
- proteomics
- cancer immunology
- translational research
- single cell
- spatial-omics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
